5.090USDMkt Cap: 793.56M USDP/E: —Last update: 2026-05-21
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap793.56M USD
Enterprise Value672.27M USD
Revenue (TTM)1.84M USD
Gross Profit-81.79M USD
Net Income (TTM)-115.18M USD
Revenue/Share0.0130 USD
Last Price5.090 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees140
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.17
PEG—
EV/EBITDA-5.77
EV/Revenue366.16
P/S432.22
P/B4.60
EPS (TTM)-0.82
EPS (Forward)-0.62
52W Range
4.80071% of range5.210
52W High5.210 USD
52W Low4.800 USD
Profitability
Gross Margin0.00%
Oper. Margin-14346.98%
EBITDA Margin0.00%
Profit Margin-4113.68%
ROE-60.80%
ROA-53.25%
Growth
Revenue Growth-81.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-92.92M USD
CapEx (TTM)1.11M USD
FCF Margin-2259.01%
FCF Yield-5.23%
Net Debt-121.29M USD
Net Debt/EBITDA1.04
Balance Sheet
Debt/Equity0.03
Current Ratio6.59
Quick Ratio6.28
Book Value/Sh1.107 USD
Cash/Share0.8060 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)8.762 USD
Target Range4.100 USD – 12.00 USD
# Analysts8
Ownership
Shares Out.155.91M
Float146.16M
Insiders13.05%
Institutions78.84%
Short Interest
Short Ratio7.3d
Short % Float26.89%
Short % Out.21.62%
Shares Short33.71M
Short (prev mo.)37.33M
Technical
SMA 503.918 (+29.9%)
SMA 2003.351 (+51.9%)
Beta2.38
S&P 52W Chg28.31%
Avg Vol (30d)2.57M
Avg Vol (10d)4.45M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—